Harbour Biomed and Yantai Lannacheng Biotechnology announced a strategic, long‑term collaboration to develop next‑generation radionuclide‑drug conjugates (RDCs) for cancer. The alliance combines Harbour Biomed’s discovery capabilities with Lannacheng’s radiochemistry and manufacturing expertise. The agreement aims to advance multiple RDC candidates through preclinical development toward clinical translation, leveraging each partner’s strengths in targeted payloads and radionuclide delivery. The partners signaled plans for joint IP and co‑development activities. The collaboration adds momentum to the growing RDC field, where industry groups are racing to marry targeted delivery with radionuclide payloads for solid tumor indications.